<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902020000400408</article-id>
<article-id pub-id-type="doi">10.29262/ram.v67i4.744</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Urticaria por frío y riesgo de anafilaxia tratada con omalizumab. A propósito de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Cold urticaria with risk of anaphylaxis treated with omalizumab. A case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bedolla-Pulido]]></surname>
<given-names><![CDATA[Tonatiuh Ramsés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mariscal-Castro]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Mendoza]]></surname>
<given-names><![CDATA[Tania]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Romero]]></surname>
<given-names><![CDATA[Jaime]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bedolla-Barajas]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Civil de Guadalajara Dr. Juan I. Menchaca Servicio de Alergia e Inmunología Clínica ]]></institution>
<addr-line><![CDATA[Jalisco ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Veracruzana Instituto de Salud Pública ]]></institution>
<addr-line><![CDATA[Veracruz ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>67</volume>
<numero>4</numero>
<fpage>408</fpage>
<lpage>412</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902020000400408&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902020000400408&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902020000400408&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: Omalizumab, un anticuerpo monoclonal anti-IgE, recientemente es utilizado como una opción en el tratamiento de la urticaria inducible.  Caso clínico: Describimos el caso de una mujer de 46 años referida al Servicio de Alergia e Inmunología del Hospital Civil de Guadalajara Dr. Juan I. Menchaca, por historia de urticaria, picazón en el cuerpo, cambios en el color de la piel tras la exposición al agua y opresión en el pecho posterior el consumo de bebidas frías; en consecuencia, ella limitaba sus actividades al aire libre y de higiene personal. Se realizaron pruebas de desafío con calor, toalla húmeda, caminata en banda sinfín y dermografismo, las cuales fueron negativas; la prueba del cubo de hielo fue positiva. Para establecer la velocidad de la formación de la roncha establecimos intervalos de exposición al frío durante uno, tres, cinco y 10 minutos; se obtuvo un resultado positivo desde el tercer minuto. Debido a la mala respuesta al tratamiento farmacológicos y a las medidas para evitar el frío, así como por la mala calidad de vida, el alto riesgo de anafilaxis y el advenimiento de la temporada de invierno, se administraron 150 mg/mes de omalizumab durante la temporada de invierno. Después de la primera dosis no se notificaron episodios de urticaria en zonas expuestas al frío; la prueba del cubo de hielo antes de la segunda dosis y en los meses siguientes fue negativa y la paciente pudo ingerir bebidas y alimentos fríos. No se produjeron reacciones adversas atribuibles al uso de omalizumab. Tres años después de la primera dosis, la paciente permanecía asintomática.  Conclusión: El caso descrito constituye uno de los primeros de urticaria inducida por el frío con riesgo de anafilaxia con respuesta positiva a omalizumab, lo que se reflejó en el control de los síntomas y la mejoría en la calidad de vida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Omalizumab, which is a monoclonal anti-IgE antibody, has recently been used as an option in the treatment of inducible urticaria.  Case report: We describe the case of a 46-year-old woman who was referred to the Department of Allergy and Immunology of &#8220;Hospital Civil de Guadalajara, Dr. Juan I. Menchaca&#8221; due to a history of hives, body itching, changes in the color of the skin after exposure to water, and chest tightness after the intake of cold beverages; therefore, she used to limit her outdoor activities and personal hygiene. We conducted challenge tests with heat, soaked towels, treadmill walks, and dermographism; which were negative. The ice cube test was positive. To establish the speed of wheal formation, we established intervals of exposure to cold of one, three, five, and ten minutes; a positive result was obtained from the third minute. Due to the poor response to the drug treatment and to measures to avoid the cold, as well as to the poor quality of life, the high risk of anaphylaxis, and the advent of winter season, omalizumab was administered at monthly doses of 150 mg during the winter season. After the first dose, there were no reports of episodes of hives in areas exposed to cold; the ice cube test was negative before the second dose and in the following months, and the patient was able to ingest cold beverages and cold food. There were no adverse reactions that could be attributable to the use of omalizumab. Three years after the first dose, the patient was still asymptomatic.  Conclusion: The described case is one of the first cases of cold urticaria with risk of anaphylaxis with a positive response to omalizumab, which was reflected in symptom control and the improvement in the quality of life.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Urticaria inducida por el frío]]></kwd>
<kwd lng="es"><![CDATA[Anafilaxia]]></kwd>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
<kwd lng="en"><![CDATA[Cold urticaria]]></kwd>
<kwd lng="en"><![CDATA[Anaphylaxis]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siebenhaar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Weller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mlynek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Magerl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Altrichter]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira-Dos Santos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acquired cold urticaria: clinical picture and update on diagnosis and treatment]]></article-title>
<source><![CDATA[Clin Exp Dermatol.]]></source>
<year>2007</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>241-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanderer]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>1990</year>
<volume>85</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>965-81</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alangari]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Twarog]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[LC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features and anaphylaxis in children with cold urticaria]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2004</year>
<volume>113</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>313-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuberbier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aberer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Asero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Abdul Latiff]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ballmer-Weber]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2018</year>
<volume>73</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1393-414</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilar-Hinojosa]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Segura-Méndez]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Lugo-Reyes]]></surname>
<given-names><![CDATA[SO.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlación de la gravedad de urticaria crónica y la calidad de vida]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2012</year>
<volume>59</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>180-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Mullins]]></surname>
<given-names><![CDATA[RJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cold urticaria: a 20-year follow-up study]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol.]]></source>
<year>2016</year>
<volume>30</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2066-71</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>2006</year>
<volume>117</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1415-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schütz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gorczyza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Staubach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>2017</year>
<volume>140</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>864-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Haynes]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Jaeschke]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Naylor]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[User&#8217;s guides to the medical literature: XXV. Evidence-based medicine: principles for applying the user&#8217;s guides to patient care]]></article-title>
<source><![CDATA[Evidence-Based Medicine Working Group. JAMA]]></source>
<year>2000</year>
<volume>284</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1290-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
